title: 18-Month mortality and perinatal exposure to zidovudine in West Africa.
abstract: OBJECTIVE
  To study mortality in African children born to HIV-1-infected mothers exposed peripartum to zidovudine.
  
  
  METHODS
  A randomized placebo-controlled trial in Abidjan and Bobo-Dioulasso. Pregnant women received either 300 mg zidovudine twice daily from 36-38 weeks' gestation, 600 mg during labour, and 300 mg twice daily for 7 days post-partum or a matching placebo. Determinants of mortality were studied up to 18 months, overall and among the infected children: treatment, centre, timing of infection, mother and child HIV disease.
  
  
  RESULTS
  There were 75 infant deaths among 407 live births. The risk of death at 18 months was 176/1000 in the zidovudine arm and 221 for placebo. Relative hazard (RH, zidovudine versus placebo) was 0.47 [95% confidence interval (CI) 0.2-1.0] up to 230 days of life. Maternal CD4 lymphocyte count < 200/mm3 (RH 2.92; CI 1.4-6.1) and child HIV-1 infection (RH 12.6; CI 6.6-24.3) increased mortality of all children born to HIV-1-infected mothers. There were 101 children infected (40 in the zidovudine group), and 51 died. Their 18 month probability of death was 590/1000 in the zidovudine group and 510 in the placebo group. Among infected children, maternal zidovudine reduced the risk of death on or before day 230 (RH 0.18; CI 0.1-0.5). Maternal CD4 lymphocyte count < 200/mm3 (RH 3.25; CI 1.3-8.4), maternal death (RH 9.65; CI 1.7-56.0), diagnosis of paediatric infection on or before day 12 (RH 18.1; CI 4.8-69.0) and between days 13 and 45 (RH 7.63; CI 2.0-29.5), clinical paediatric AIDS (RH 5.37; CI 2.3-12.7) were risk factors for death in HIV-1-infected children.
  
  
  CONCLUSIONS
  Mother-to-child transmission reduction by zidovudine is safe and beneficial to African children. The mortality of HIV-1-infected children is high. Peripartum maternal zidovudine exerts a protective effect for at least 8 months.
authors.affiliation: Unité INSERM no. 330, ISPED, Université Victor Segalen Bordeaux 2, Bordeaux, France. francois.dabis@isped.u-bordeaux2.fr
authors.forename: F
authors.initials: F
authors.lastname: Dabis
authors.forename: N
authors.initials: N
authors.lastname: Elenga
authors.forename: N
authors.initials: N
authors.lastname: Meda
authors.forename: V
authors.initials: V
authors.lastname: Leroy
authors.forename: I
authors.initials: I
authors.lastname: Viho
authors.forename: O
authors.initials: O
authors.lastname: Manigart
authors.forename: L
authors.initials: L
authors.lastname: Dequae-Merchadou
authors.forename: P
authors.initials: P
authors.lastname: Msellati
authors.forename: I
authors.initials: I
authors.lastname: Sombie
mesh_terms: D000328:Adult; D000354:Africa, Western / Q000453:epidemiology; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality / Q000635:transmission; D015497:HIV-1; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D015999:Multivariate Analysis; D016017:Odds Ratio; D011247:Pregnancy; D016016:Proportional Hazards Models; D012367:RNA, Viral / Q000032:analysis; D012306:Risk; D012307:Risk Factors; D015215:Zidovudine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D012367:RNA, Viral; D015215:Zidovudine